Skip to main content
رجوع
NAMS logo

NewAmsterdam Pharma Company N.V.

جودة البيانات: 100%
NAMS
NASDAQ Healthcare Biotechnology
KWD 30.06
▲ KWD 0.05 (0.17%)
القيمة السوقية: 3.46B
نطاق اليوم
KWD 28.99 KWD 30.65
نطاق 52 أسبوعًا
KWD 14.06 KWD 42.00
حجم التداول
632,741
متوسط 50 يوم / 200 يوم
KWD 32.70 / KWD 29.92
الإغلاق السابق
KWD 30.01

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (627 نظير)

المقياس السهم وسيط القطاع
P/E -17.0 0.3
P/B 5.1 2.9
ROE % -28.3 3.7
Net Margin % -905.7 3.8
Rev Growth 5Y % 10.0
D/E 0.0 0.2

السعر المستهدف للمحللين

Hold
KWD 47.200 +57.0%
Low: KWD 37.000 High: KWD 55.000
ربحية السهم المستقبلية
-KWD 1.913
الإيرادات المقدّرة
28 M

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 KWD 3.664
-KWD 0.005 – KWD 13.821
1.3 B 6
FY2029 KWD 1.590
-KWD 0.002 – KWD 5.998
830 M 6
FY2028 -KWD 0.215
-KWD 0.810 – KWD 0.000
430 M 7

النقاط الرئيسية

Debt/Equity of 0.00 — conservative balance sheet
Negative free cash flow of -148.03M
PEG of 0.62 suggests growth is underpriced
Capital efficient — spends only 1.09% of revenue on capex

النمو

Revenue Growth (5Y)
N/A
Revenue (1Y)-50.61%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-28.29%
ROIC-24.76%
Net Margin-905.74%
Op. Margin-1002.90%

الأمان

Debt / Equity
0.00
Current Ratio7.88
Interest Coverage0.00

التقييم

P/E Ratio
-16.96
P/B Ratio5.06
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -50.61% Revenue Growth (3Y) 26.38%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 22.50M Net Income (TTM) -203.82M
ROE -28.29% ROA -26.49%
Gross Margin 99.74% Operating Margin -1002.90%
Net Margin -905.74% Free Cash Flow (TTM) -148.03M
ROIC -24.76% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.00 Current Ratio 7.88
Interest Coverage 0.00 Dividend Yield 0.00%
Valuation
P/E Ratio -16.96 P/B Ratio 5.06
P/S Ratio 153.59 PEG Ratio 0.62
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 3.46B Enterprise Value 2.97B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 22.50M 45.56M 14.09M 102.69M 0.0
Net Income -203.82M -241.60M -176.94M -22.63M -41.79M
EPS (Diluted) -1.75 -2.56 -2.15 -1.19 -3.34
Gross Profit 22.44M 45.56M 14.09M 102.69M 0.0
Operating Income -225.68M -176.29M -182.97M -3.56M -34.98M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 769.28M 864.62M 347.10M 478.50M 67.99M
Total Liabilities 85.85M 107.12M 58.70M 48.43M 11.36M
Shareholders' Equity 683.43M 757.50M 288.39M 430.07M 56.63M
Total Debt 202,000.0 448,000.0 60,000.0 126,000.0 186,511.0
Cash & Equivalents 490.00M 771.74M 340.45M 467.73M 60.38M
Current Assets 675.70M 863.41M 346.79M 477.98M 66.96M
Current Liabilities 85.79M 106.92M 49.90M 36.06M 11.24M